Regulatory FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients FDAThe U.S.Gene Therapy PlatformRead full story pharminent June 2, 2026 (Last updated: June 3, 2026) FDA The U.S. Gene Therapy Platform Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ASCO: Merck overshadowed by upstart biotechs but TROP2 plans begin to pay offNext: ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
